High-Dose-Rate Brachytherapy as Monotherapy for Low- and Intermediate-Risk Prostate Cancer. Oncological Outcomes After a Median 15-Year Follow-Up

IntroductionTo evaluate the oncological outcome of high dose rate (HDR) brachytherapy (BRT) as monotherapy for clinically localised prostate cancer (PCA).Material and MethodsBetween January 2002 and February 2004, 141 consecutive patients with clinically localised PCA were treated with HDR-BRT monot...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Manuel Behmueller, Nikolaos Tselis, Nikolaos Zamboglou, Eleni Zoga, Dimos Baltas, Claus Rödel, Georgios Chatzikonstantinou
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2021-12-01
Edice:	Frontiers in Oncology
Témata:	prostate cancer HDR-brachytherapy monotherapy biochemical relapse free survival toxicity
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fonc.2021.770959/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!